Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test.

Eack SM, Greeno CG, Pogue-Geile MF, Newhill CE, Hogarty GE, Keshavan MS.

Schizophr Bull. 2010 Mar;36(2):370-80. doi: 10.1093/schbul/sbn091. Epub 2008 Jul 22.

2.

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR.

Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.

PMID:
18172019
3.

A meta-analysis of cognitive remediation in schizophrenia.

McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT.

Am J Psychiatry. 2007 Dec;164(12):1791-802.

4.

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG.

Arch Gen Psychiatry. 2007 Oct;64(10):1115-22.

PMID:
17909123
5.

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.

Am J Psychiatry. 2007 Oct;164(10):1593-602.

PMID:
17898352
6.

Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.

Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J.

Am J Psychiatry. 2007 Oct;164(10):1585-92. Erratum in: Am J Psychiatry. 2007 Nov;164(11):1766.

PMID:
17898351
7.

Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial.

Wykes T, Newton E, Landau S, Rice C, Thompson N, Frangou S.

Schizophr Res. 2007 Aug;94(1-3):221-30. Epub 2007 May 23.

PMID:
17524620
8.

Durability and mechanism of effects of cognitive enhancement therapy.

Hogarty GE, Greenwald DP, Eack SM.

Psychiatr Serv. 2006 Dec;57(12):1751-7.

PMID:
17158490
9.

Cognitive enhancement therapy improves emotional intelligence in early course schizophrenia: preliminary effects.

Eack SM, Hogarty GE, Greenwald DP, Hogarty SS, Keshavan MS.

Schizophr Res. 2007 Jan;89(1-3):308-11. Epub 2006 Oct 19.

10.

The functional significance of social cognition in schizophrenia: a review.

Couture SM, Penn DL, Roberts DL.

Schizophr Bull. 2006 Oct;32 Suppl 1:S44-63. Epub 2006 Aug 17. Review.

11.

Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia.

Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF.

Am J Psychiatry. 2006 Mar;163(3):448-54.

PMID:
16513866
12.

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Perkins DO, Gu H, Boteva K, Lieberman JA.

Am J Psychiatry. 2005 Oct;162(10):1785-804. Review.

PMID:
16199825
13.

Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia.

Herbener ES, Hill SK, Marvin RW, Sweeney JA.

Am J Psychiatry. 2005 Sep;162(9):1746-8.

PMID:
16135639
14.

Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia.

Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE.

Schizophr Res. 2005 Oct 1;78(1):27-34.

PMID:
15964177
15.

Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study.

Ueland T, Rund BR.

Acta Psychiatr Scand. 2005 Mar;111(3):193-201.

PMID:
15701103
16.

Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis.

Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD.

Am J Psychiatry. 2005 Jan;162(1):71-8.

PMID:
15625204
17.

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.

Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R.

Arch Gen Psychiatry. 2004 Sep;61(9):866-76.

PMID:
15351765
18.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR.

Biol Psychiatry. 2004 Sep 1;56(5):301-7. Review.

PMID:
15336511
19.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA.

Am J Psychiatry. 2004 Jun;161(6):985-95.

PMID:
15169686
20.

Supplemental Content

Support Center